Phase
Condition
Digestive System Neoplasms
Gastric Cancer
Carcinoid Syndrome And Carcinoid Tumours
Treatment
N/AClinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Men and women must be 18 years of age or older
A current diagnosis of advanced, unresectable GEP-NET
Provided written informed consent to participate in the study
Currently receiving lanreotide or octreotide LAR and has received at least one priorinjection of current somatostatin analogues (SSA).
Exclusion
Exclusion Criteria:
Receiving treatment with lanreotide or octreotide LAR as part of a clinical trial
Scheduled to receive a dose of lanreotide or octreotide LAR that would necessitatemore than 1 injection on the same day
Scheduled to receive any other treatment in the infusion center/room on the same dayand as part of the same appointment
Known hypersensitivity to somatostatin analogues
Study Design
Connect with a study center
The University of Arizona Cancer Center
Tucson, Arizona 85719
United StatesSite Not Available
The University of Arizona Cancer Center
Tuscan, Arizona 85719
United StatesSite Not Available
Ochsner Medical Center Kenner
Kenner, Louisiana 70065
United StatesSite Not Available
Mercy Medical Center
Baltimore, Maryland 21202
United StatesSite Not Available
National Translational Research Group
East Setauket, New York 11733
United StatesSite Not Available
Oncology Specialists of Charlotte
Charlotte, North Carolina 28207
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.